Empire Genomics

Name

Empire Genomics

Legal name

Empire Genomics

Website

https://empiregenomics.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Cytogenetics Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV) (HLAGANAJ)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• FISH probe manufacturing
• In situ hybridization reagents
• Cytogenetics diagnostics
• Molecular pathology automation
• Chromosomal abnormality detection

Headquarters

HQ city

Buffalo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. FISH Probes: Sale of fluorescent in situ hybridization probes including manual probes, automated probes, ASR, RUO, and CE-IVD products. Pricing varies by probe type, kit size, and regulatory status (concentrate vs predilute).
2. FISH Ancillaries: Supporting reagents including hybridization buffers, wash buffers, pre-treatment kits, DAPI with antifade, and nick translation kits.
3. Custom Probe Services: Custom FISH and CISH probe design and manufacturing services, typically delivered within two weeks.
4. Full-Service FISH Processing: End-to-end FISH processing services providing adaptable support from sample to signal for laboratories needing outsourced testing.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Empire Genomics manufactures and sells Fluorescence In Situ Hybridization (FISH) probes, RNA-ISH (NISH) probes, and ancillary reagents used to detect chromosomal abnormalities and gene expression in clinical diagnostics and research laboratories. The company complements its probe catalog (2,000+ items) with automated staining platforms (NeoPATH Pro, Biodot, ONCORE Pro), custom probe design services, and full-service FISH processing for outsourced testing.

Product overview

Empire Genomics offers a comprehensive FISH testing solutions portfolio built around a platform-plus-products architecture. The core offering centers on FISH Probes available in multiple formats (Single Color, Dual Color, Break Apart, Fusion, Control Probes) for detecting chromosomal abnormalities in clinical and research settings. This is complemented by the NISH Probes product line—ready-to-use RNA-ISH research probes powered by HCR™ Pro technology—for the NeoPATH Pro automation platform. Supporting the probe portfolio are FISH Ancillaries (hybridization buffers, pre-treatment kits, wash buffers) and Custom FISH Probe Design services enabling any-target probe creation. The company also provides Full-Service FISH Processing as a laboratory service option. Automation is enabled through three dedicated platforms: NeoPATH Pro for tissue FISH, Biodot for hematology applications, and ONCORE Pro® for urine cytology. The portfolio spans over 2,000 probe catalog items, 50+ automated probes, and is backed by an extensive BAC library originating from the Human Genome Project.

Differentiator

Problem solved

Functional benefit

Brands

• NISH (Novel ISH): Ready-to-use RNA in situ hybridization probes for the NeoPATH Pro automated staining platform, powered by HCR™ Pro technology.
• NeoPATH Pro
• Swish Probes

Products and services

• FISH Probes Fluorescence In Situ Hybridization (FISH) probes for detecting chromosomal abnormalities, available in multiple formats including Single Color, Dual Color, Break Apart, Fusion, and Control Probes for clinical and research applications across FFPE, cytology, and hematology samples.
• NISH Probes (RNA-ISH) Ready-to-use RNA-ISH research probes powered by HCR™ Pro chemistry for the NeoPATH Pro automated staining platform. Includes HPV probes, ISH probes (KAPPA, LAMBDA, EBER, CMV, ERBB2, ALBUMIN), and control probes for gene expression mapping and biomarker characterization with run times as little as 5.5 hours.
• NeoPATH Pro Automated Staining Platform Fully automated staining platform for tissue FISH testing that delivers automated FISH workflows from start to finish, consolidating ISH, IHC, and FISH workflows on a single instrument for clinical and research laboratories.
• Biodot Automation Platform Automation platform designed for hematology (HEME) applications, enabling automated FISH workflows for blood-related diagnostic testing.
• ONCORE Pro® Automated Staining Platform Automated staining platform designed for urine cytology applications, providing automated FISH workflows for urological diagnostic testing.
• FISH Ancillaries Essential supporting reagents including SwiftFISH® Fast Hybridization Buffer, DAPI w/ Antifade, Wash Buffers, FFPE Pre-Treatment Kit, Cyto Pre-Treatment Kit, Hybridization Buffer, and Nick Translation Kit—designed to enhance the accuracy, efficiency, and quality of FISH and CISH results.
• Custom FISH Probe Design Service Custom probe design service allowing creation of FISH and CISH probes for any target, with design turnaround in two weeks or less, delivered through advanced FISH specialist engagement.
• Full-Service FISH Processing End-to-end FISH processing service providing adaptable outsourced testing support from sample preparation to signal detection for laboratories that need external testing capability.
• PTEN del-TECT™ Four Color FISH Probe Research-use-only four-color FISH assay detecting PTEN gene deletions with flanking controls (WAPAL/BMPR1A, FAS) and CEP10 centromere probe to distinguish true deletions from FFPE artifacts.

Quantifiable outcome

• 5.5-hour turnaround for automated RNA-ISH (NISH) on NeoPATH Pro vs. traditional multi-day workflows
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Molecular InstrumentscoreStrategic or Co-development Partner · 5 May 2026Empire Genomics and Molecular Instruments launched NISH (Navigated ISH) powered by HCR™ Pro technology, described as the largest ready-to-use, fully automated ISH library for research, exclusively available on the NeoPATH Pro automated staining platform. The collaboration aims to address barriers to RNA-ISH adoption including workflow complexity, limited automation, and probe access for research laboratories conducting biomarker and translational research.
• GMED (Notified Body)minorOthersGMED is the Notified Body partner for Empire Genomics IVDR transition, overseeing compliance with EU Regulation 2017/746. This partnership ensures continuous product availability during transition from IVDD to IVDR certification, expected by Q4 2026.

Scale indicators10 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Abbott Molecular: Abbott Molecular (Vysis) is the historical market leader in FISH probes for oncology and cytogenetics, offering a directly overlapping probe portfolio plus bundled instrument platforms. It competes head-to-head with Empire Genomics across clinical diagnostics and cancer center customers.
• ZytoVision: ZytoVision manufactures FISH and CISH probes for clinical diagnostics and research, with a comparable probe catalog and a focus on pathology and cytogenetics applications. It is one of the closest direct competitors to Empire Genomics in mid-sized FISH probe markets.
• MetaSystems: MetaSystems provides FISH probes alongside automated imaging and analysis platforms for cytogenetics. It competes with Empire in the FISH probe consumable market and is especially relevant given Empire's automation platform strategy.
• Cytocell (Revvity): Cytocell, now part of Revvity (formerly PerkinElmer), is a leading FISH probe manufacturer with a deep oncology and hematology portfolio. It directly competes with Empire Genomics for clinical cytogenetics lab customers and offers bundled probe-instrument solutions.

Others

• BioCare Medical: BioCare Medical is the sister/parent entity to Empire Genomics within the Agilent diagnostics group, specializing in IHC and automation. While not a direct FISH competitor, the two share a common owner and overlapping customer base in anatomic pathology labs.
• Leica Biosystems (Danaher): Leica Biosystems, part of Danaher's diagnostics platform, supplies IHC, ISH, and FISH staining instruments and reagents used by pathology labs. It competes with Empire on automation platforms (e.g., vs. NeoPATH Pro) and adjacent reagent categories.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a global molecular diagnostics incumbent offering FISH probes (through its Ventana/legacy Roche Molecular portfolio) alongside PCR, NGS, and tissue diagnostics. It competes broadly with Empire at large hospital and reference lab accounts.
• Qiagen: Qiagen is a major molecular diagnostics and sample technologies provider with a portfolio that overlaps Empire's customer base in oncology and translational research labs. While not primarily a FISH competitor, it competes for the same molecular diagnostics budgets.
• Hologic: Hologic operates a molecular diagnostics franchise (including the Diagenode and former Grifols partnership assets) with FISH-adjacent products in cytogenetics and women's health oncology. It competes for the same clinical lab budgets and instrument placements.
• Agilent Technologies: Agilent is the parent conglomerate of Empire Genomics and operates broadly across life sciences instrumentation, diagnostics, and applied markets. While not a direct peer, it is the ultimate parent and provides the strategic and operational backdrop for Empire's competitive positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EmpireGenomics
• Facebookfacebook.com/EmpireGenomics
• LinkedInlinkedin.com/company/empire-genomics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Empire Genomics